Observational Study

Hepatitis B virus outreach to immigrant population in Greater Boston Area: Key to improving hepatitis B knowledge

Raissa Djoufack, Scarlett Se Yun Cheon, Aisha Mohamed, Fatou Faye, Korka Diouf, Richard Colvin, James Morrill, Ann-Marie Duffy-Keane, Ponni Perumalswami, Gonzague Jourdain, Dahlene Fusco

Raissa Djoufack, Universite des Montagnes, Bangangte 61710, Cameroon

Scarlett Se Yun Cheon, Wellesley College, Wellesley, MA 02481, United States

Aisha Mohamed, Cooper Medical School of Rowan University, Camden, NJ 08103, United States

Fatou Faye, Korka Diouf, Suffolk University, Boston, MA 02108, United States

Richard Colvin, James Morrill, Ann-Marie Duffy-Keane, Dahlene Fusco, Division of General Internal Medicine, MGH, Boston, MA 02114, United States

Ann-Marie Duffy-Keane, MGH Community Health Associates, Revere, MA 02114, United States

Ponni Perumalswami, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States

Gonzague Jourdain, Institut de Recherche pour le Développement, Marseille 13000, France

Gonzague Jourdain, Chiang Mai University, Chiang Mai 50200, Thailand

Gonzague Jourdain, Harvard T.H. Chan School of Public Health, Boston, MA 02115, United States

Dahlene Fusco, Division of Infectious Disease, Department of Medicine, Vaccine and Immunotherapy Center, MGH, Boston, MA 02129, United States

Dahlene Fusco, Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, United States

ORCID Number: Raissa Djoufack (0000-0002-1185-7814);

Scarlett Se Yun Cheon (0000-0002-8527-8938); Aisha Mohamed (0000-0002-7179-4093); Fatou Faye (0000-0002-4298-068X); Korka Diouf (0000-0003-2087-2298); Richard Colvin (0000-0001-5851-7019); James Morrill (0000-0002-2684-8531); Ann-Marie Duffy-Keane (0000-0002-6841-9743); Ponni Perumalswami (0000-0003-3070-3906); Gonzague Jourdain (0000-0002-3365-7020); Dahlene Fusco (0000-0002-5629-0110).

Author contributions: Djoufack R, Cheon SSY, Mohamed A, Faye F, Diouf K, Colvin R, Morrill J, Duffy-Keane AM, Perumalswami P, Jourdain G and Fusco D all helped conduct this study and contributed to the manuscript; Jourdain G, Fusco D, Djoufack R and Cheon SSY analyzed the data; Fusco D designed this study.

Supported by Gilead Sciences (DNF).

Institutional review board statement: This study was reviewed and approved by the Partners/Massachusetts General Hospital Institutional Review Board.

Informed consent statement: All study participants provided informed verbal consent in native language or in English.

Conflict-of-interest statement: Dahlene Fusco has received support towards this study from Gilead.

Data sharing statement: Verbal consent was obtained; data are anonymized and risk of identification is low. No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/
A teaching session targeting Boston Immigrants at-risk for HBV helped improve scores on HBV knowledge questionnaires. Outreach may empower at-risk patients to pro-actively seek HBV care.

Key words: Hepatitis B virus; Outreach; Linkage to care; Immigrant; Boston

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Awareness is the key to the mitigation of transmittable diseases such as hepatitis B virus (HBV). Therefore, characterizing the baseline understanding of HBV, and improving that baseline, are the first steps toward improving HBV linkage to care among at-risk persons. To characterize and improve the baseline understanding of HBV we performed HBV teaching sessions with pre and post session questionnaires in multiple community venues in and around Boston. These sessions revealed that (1) baseline understanding of risks related to HBV are limited; and (2) a brief teaching session can significantly improve understanding of HBV risks.

INTRODUCTION

Roughly 240 million people worldwide are chronically infected with hepatitis B virus (HBV), defined as hepatitis B surface antigen (HBsAg) positive for over 6 mo[1]. Over 686000 people are estimated to die every year due to complications of HBV infection, including cirrhosis and liver cancer[11]. HBV prevalence varies worldwide, with highest prevalence in sub-Saharan Africa and East Asia, where between 5%-10% of the adult population is chronically infected[1,2,13]. While precise data on some countries in sub-Saharan Africa are limited, prevalence estimates have been generated from studies of migrant populations, and estimate high prevalence[5,17]. Roughly half of the 800000 to 1.4 million United States residents chronically infected with HBV were born in other countries. The Center for Disease Control and Prevention current recommendations for HBV testing and evaluation have evolved during the last two decades to include more and more persons born abroad (currently countries with HBsAg prevalence of greater than 2%). Appropriate

CONCLUSION

A teaching session targeting Boston Immigrants at-risk for HBV helped improve scores on HBV knowledge questionnaires. Outreach may empower at-risk patients to pro-actively seek HBV care.

Key words: Hepatitis B virus; Outreach; Linkage to care; Immigrant; Boston

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Awareness is the key to the mitigation of transmittable diseases such as hepatitis B virus (HBV). Therefore, characterizing the baseline understanding of HBV, and improving that baseline, are the first steps toward improving HBV linkage to care among at-risk persons. To characterize and improve the baseline understanding of HBV we performed HBV teaching sessions with pre and post session questionnaires in multiple community venues in and around Boston. These sessions revealed that (1) baseline understanding of risks related to HBV are limited; and (2) a brief teaching session can significantly improve understanding of HBV risks.

INTRODUCTION

Roughly 240 million people worldwide are chronically infected with hepatitis B virus (HBV), defined as hepatitis B surface antigen (HBsAg) positive for over 6 mo[1]. Over 686000 people are estimated to die every year due to complications of HBV infection, including cirrhosis and liver cancer[11]. HBV prevalence varies worldwide, with highest prevalence in sub-Saharan Africa and East Asia, where between 5%-10% of the adult population is chronically infected[1,2,13]. While precise data on some countries in sub-Saharan Africa are limited, prevalence estimates have been generated from studies of migrant populations, and estimate high prevalence[5,17]. Roughly half of the 800000 to 1.4 million United States residents chronically infected with HBV were born in other countries. The Center for Disease Control and Prevention current recommendations for HBV testing and evaluation have evolved during the last two decades to include more and more persons born abroad (currently countries with HBsAg prevalence of greater than 2%). Appropriate
HBV care can both prevent progression of HBV related disease in infected persons and may decrease the likelihood of spread to others\cite{1}.

A recent study in the United States found that of 277 health care providers, only 42% reported performing HBV screening in over 50% of patients at risk for HBV\cite{12}. This study identified language as a major barrier to care. Providers speaking an Asian language or caring for > 25% Asian patients were more likely to screen for HBV. Fewer studies have focused on barriers to HBV care among African immigrants in the United States, though they are at high risk, similar to Asian immigrants\cite{3,15}. Between 1980 and 2009, there was a seven-fold increase in the number of African-born United States residents, underscoring a need for HBV outreach targeting these at-risk populations\cite{3,9,10}. While the United States Department of Health and Human Services have initiated efforts to increase HBV services among minority populations, there is an ongoing need for population-specific HBV linkage-to-care strategies\cite{3,6,8}.

Prior studies among immigrants in the New York City area have revealed that HBV outreach to immigrants from countries where HBV is endemic, including immigrants from Sub Saharan Africa, leads to improved HBV diagnosis and engagement in follow up care\cite{3,7,14,16,18}. Hence, including HCC screening in those who are infected Awareness and knowledge of the disease are prerequisites to screening for HBV infection, then monitoring and treatment. We undertook a study in Boston, which has a large Sub-Saharan African immigrant population\cite{4} to determine (1) baseline HBV knowledge among Greater Boston Area immigrants from HBV endemic regions; and (2) whether a brief teaching intervention could improve HBV knowledge among these at-risk persons.

**MATERIALS AND METHODS**

**Ethical approval**

Approval by the Partners/Massachusetts General Hospital Institutional Review Board (Protocol 2014P000921, DNF) was obtained prior to initiating this study. Verbal consent was provided by all participants.

**Outreach sessions**

After obtaining IRB approval, six “HBV Linkage to Care” community outreach sessions were conducted in the Greater Boston Area targeting foreign-born communities. Although the study targeted foreign born persons, we did not exclude any United States born persons who attended from participating. Event one was held at a Somali restaurant. Event two was held at a Community Health Center. Events three, four, and five were held at private residences/recreation rooms in apartment complexes throughout Boston. Event six was held at a Turkish community center. Food was provided for hospitality at each event. Participants for each event were solicited by word of mouth by a local community outreach liaison, including several members of the Somali community. Each event included the following structure: participants were greeted and informed that the session was part of a study, and verbal consent obtained in native language or in English. In person interpreters were present for Somali events (Somali speaking), Cambodian event (Khmer speaking), and the Turkish Center event (Arabic and Spanish speaking). Interpreters translated the teaching session.

![Figure 1 Perceived hepatitis B virus risk by country: responses to “How high is your risk for having hepatitis B infection, on a scale of 1 to 5?”. In the pre session, 98 participants answered this question with a mean response score of 1.33. In the post session, 53 participants answered and a mean response score of 3.13 was obtained. There is a statistically significant increase in the perceived risk of hepatitis B with a P value of < 0.05.](image-url)
verbally and assisted participants in questionnaire completion. Participants were then asked to complete a pre-session (baseline) questionnaire within about 30 min. The questionnaire was developed by physicians based on HBV clinical experience in Community Health Centers serving largely immigrant populations. Participants were asked three types of questions (1) six questions answered with a Likert-type scale where responses were scored along a range from 1 to 5; (2) seven open ended questions; and (3) ten true/false questions (Figure S1). The complete teaching session was developed by the study team and then presented to community-based clinicians who manage patients with viral hepatitis and outreach workers serving both immigrant and non-immigrant health center populations for input and editing prior to IRB submission and approval. During outreach events, the teaching session was presented by a member of the study team and took approximately 45 min including time for questions after the session. Participants were then asked to complete a post-session questionnaire (identical to the pre-session questionnaire), though a significant number of participants left without completing the post-session questionnaire. Of note, participants were not instructed to complete their questionnaires alone, and many participants worked in small subgroups, completing questionnaires together. At the end of each event, participants were given (1) a navigator card, in English, which stated a request for HBV testing (Figure S2); and (2) a list of local HBV providers verified to be accepting new patients and their contact information, with contents of each document translated by interpreters. The list of local providers was developed by members of the study team who identified five major medical centers and two community health centers in the Greater Boston area with whom linkage to care agreements were established by contacting outpatient Gastroenterology and/or Infectious Disease clinics at each site, and verification of each site contact information and ongoing acceptance of new patients. All participation was anonymous with no study identifiers being collected.

Data analysis and statistics

All questionnaires were stored in a secure file cabinet accessed only by study staff for entry into a secure database. We used the Kruskal-Wallis test or Fisher’s exact test for comparisons. A P value < 0.05 was considered significant, with no correction for multiple comparisons.

RESULTS

There were 101 participants in the pre-session questionnaire, 56 of whom also completed the postsession questionnaires. All 101 pre-session questionnaires were included in data. Participants were male and female, ranging from 19 to 87 years of age (Figure 1). Several female-only teaching sessions were requested by the Somali community leader, leading to greater number of female (62) than male (26) participants overall (Table 1). The study population included immigrants born in 21 countries outside the United States, as well as seven participants born in the United States (Table 1, Figure S3). Countries with the greatest number of participants were Somalia (44%), Morocco (10%), and Cameroon (8%) (Table 1, Figure S3). The mean number of years the participants had spent in the United States was 13 (SD = 12), with 24% participants having been in the United States for less than 5 years (Table 1).

Likert-type scale responses

Responses to the “How high is your risk for having HBV infection?” question were scaled from 1 (lowest risk) to 5 (highest risk) (Figure 1, Figure S1). For this question of perceived HBV risk, mean response scores from pre-teaching session participants from all countries scored at or near 1 except Somalia (1.78). Following the teaching session, mean perceived risk scores increased of participants born in the United States for less than 5 years (Table 1).
United States (logistic regression, data not shown). Among reasons for possible increased risk of infection, foreign origin was the most cited (40%). Interestingly, the major cause of infection in high prevalence countries, i.e., mother-to-child transmission, was cited only once, post teaching.

Open ended questions
Participants were asked 5 open-ended questions regarding HBV testing including barriers, associated stigma and treatment knowledge (Figure S1). For the open-ended question "What makes your risk for HBV infection higher?" the percent of participants responding "Country of origin" increased slightly from 40% (pre) to 44% (post), following the teaching session (Table 2). The percent of participants answering "I am not at risk" decreased from 20% (pre) to 12% (post) following the teaching session (Table 2). Responses to additional open ended questions revealed that 73% (pre) -81% (post) of participants reported that HBV testing is important, and 31%-40% of participants cited concerns regarding insurance coverage as a barrier to access to HBV care (Table 3).

True/False questions related to HBV knowledge
Participants were asked to answer ten true/false questions prior to (pre) and after (post) the teaching session (Figure 2, Table 4). The percentage of participants answering each true/false HBV question correctly increased following the teaching session (Figure 2, Table 4), from a mean of 5.5 (report SD) out of 10 correct answers, to a mean of 7.6 (report SD) out of 10 correct answers ($P < 0.001$). For the question "The only way to get HBV is through sexual contact" (false), the percentage of correct answers increased from 45 (pre) to 61 (post) ($P = 0.04$). For the question "If you have HBV but no symptoms, taking a small sample of blood. Hepatitis B infection can cause scarring of the liver and liver cancer." (false), the percentage of correct answers increased from 53 (pre) to 77 (post) ($P = 0.006$). For the question "HBV can cause scarring of the liver and liver cancer" (true), the percentage of correct answers increased from 58 (pre) to 79 (post) ($P = 0.01$). For the question "There is no treatment for HBV" (false), the percentage increased from 50 (pre) to 66 (post), but was not statistically significant ($P = 0.06$). For the question "If you do not have HBV, there is a vaccine that can prevent HBV" (true), the percentage increased from 62 (pre) to 75 (post) ($P = 0.03$).
immigrants, suggesting a particular openness to seek
number of participants by far was among Somali
in the Greater Boston Area, as well as the ability to
seline HBV knowledge state of at-risk immigrants
The goals of this study were to determine the ba-
DISCUSSION
not accessible due to political instability.
available at some sites in their native country, were
Several Somali participants stated that access to
spent multiple years in Kenya in refugee camps prior
although they were originally from Somalia, they had
Several participants from Somalia clarified that,

Table 2  Perceived hepatitis b risk before and after teaching
session n (%)  

| Perceived at least some risk of being HBV infected | Pre session (n = 101) | Post session (n = 56) | P value |
|--------------------------------------------------|----------------------|----------------------|---------|
| Mean                                             | 1.34                 | 2.26                 | < 0.001 |
| At least some risk                                | 11 (11)              | 35 (70)              |         |
| Gender                                           |                       |                      |         |
| Female                                           | 7 (12)               | 24 (71)              |         |
| Male                                             | 3 (12)               | 5 (63)               |         |
| Age (yr)                                         |                       |                      |         |
| < 45                                             | 2 (5)                | 23 (70)              |         |
| > 45                                             | 8 (19)               | 9 (75)               |         |
| Years in the United States                       |                       |                      |         |
| < 5                                              | 2 (9)                | 11 (79)              |         |
| > 5                                              | 9 (13)               | 19 (63)              |         |
| Continent of Origin                              |                       |                      |         |
| Africa                                           | 11 (16)              | 19 (73)              |         |
| Asia                                             | 0                    | 6 (67)               |         |
| Europe                                           | 0                    | 4 (57)               |         |
| America                                          | 0                    | 1 (30)               |         |
| Reasons why your risk is high                    |                       |                      |         |
| Country of origin                                | 30 (40)              | 22 (44)              |         |
| Needle exposure                                   | 15 (20)              | 9 (18)               |         |
| Sexual exposure                                   | 14 (19)              | 9 (18)               |         |
| I don’t know                                     | 11 (15)              | 9 (18)               |         |
| I am not at risk                                 | 15 (20)              | 6 (12)               |         |
| Other reasons1                                   | 8 (10)               | 9 (18)               |         |
| Mother to child transmission                     | 0                    | 1 (0.02)             |         |

1Africa (Cameroon, Gambia, Kenya, Libya, Morocco, Senegal, Somalia, Togo, Uganda), Asia (Cambodia, South Korea, Uzbekistan), Europe (France, Greece, Turkey), America (Brazil, Canada, Colombia, Costa Rica, Mexico, United States); 2Other reasons: Pre (genetic, food, public transportation, wound, job, utensils, contact with blood, sharing blade), Post (lack of information); Participant answers to perceived HBV risk were categorized as either Low risk, if answered 1, or Some risk, for answers of more than 1 in a Likert Scale (1= low; 5 = high risk); HBV: Hepatitis B virus.

(post), but, again, was not statistically significant (P = 0.2).

Other points raised during discussion
Several participants from Somalia clarified that, although they were originally from Somalia, they had spent multiple years in Kenya in refugee camps prior to their arrival to the United States, disrupting both formal education and access to health care for many. Several Somali participants stated that access to vaccines prior to immigration, even when they were available at some sites in their native country, were not accessible due to political instability.

DISCUSSION
The goals of this study were to determine the baseline HBV knowledge state of at-risk immigrants in the Greater Boston Area, as well as the ability to improve HBV understanding through a brief teaching intervention. Of all immigrant populations, the highest number of participants by far was among Somali immigrants, suggesting a particular openness to seek health education and highly effective community networking (recruiting participants) within this community in Boston, likely due to the pre-existing community network established by our Somali liaison.

There were several limitations to our study. One limitation was the lack of retention of participants for the entire event, with many (45%) participants leaving before answering the post-session questionnaire. Furthermore, the sample size of this study was relatively small as this was exploratory research, and there had been no prior calculation of a target sample size based on a specific hypothesis to be tested. The data collected in our study may help determine the design and sample size of future studies. Another limitation was language barrier, despite presence of in-person interpreters, due to the high ratio of participants per interpreter; and failure to obtain education information, which may have influenced questionnaire responses, from participants. Another limitation of this study was that the questionnaire was not validated. There was some difficulty interpreting changes in answers to open ended questions between pre- and post- teaching sessions. For example, for the open-ended question "Why is it important to test those at risk for HBV", in the pre-session questionnaire, 24% of participants answered that HBV testing could prevent the spread of infection, whereas in the post-session questionnaire, 16% of participants answered that HBV testing could prevent spread of infection. In contrast, post session responses to this question increased for "initiate treatment early" (from 16% to 20%), and "prevent long term complications" (from 10% to 16%), indicating that participants likely shifted the focus of their answers, without any clear evidence of loss of knowledge. These results highlight the complexity of interpreting open-ended questions in a quantitative manner, an area for improvement in future studies. Another limitation is that the impact of this education intervention on longer term knowledge retention as well as accessing HBV screening is not known and should be included in a future study.

While knowledge overall improved after the teaching intervention (report the overall change score with P value), there were two areas that demonstrated more room for improvement including vaccination and treatment. During teaching sessions, it was explained that treatment for HBV exists, but is not curative, and must be taken for the long-term, rather than a discrete time course. It is possible that this description of a suppressive but not curative treatment led to confusion. Regarding vaccines, it was explained that they are effective if given prior to infection, but not if given once someone is already infected. This point was repeated several times in an attempt to clearly communicate that the simple receipt of an HBV vaccine does not eradicate HBV if a person from an endemic area was already infected. In fact, the authors note that communication of this message was one of the
reasons for the study: multiple patients interactions reveal that patients often perceive that they cannot be HBV infected because they have been vaccinated, although some may have been infected before vaccination. Results of this study reveal that, while knowledge related to HBV vaccines and treatments did improve following teaching intervention, additional refinement in these areas to the teaching intervention could enhance HBV knowledge. Specifically, additional slides illustrating the populations in whom vaccine will and will not work should be included.

This study revealed that outreach events, in accessible and hospitable community venues, can provide an effective forum for HBV health teaching sessions to raise HBV awareness for at-risk immigrants in the Greater Boston Area. Events held in Health

| Variable                                             | Pre (%) | Post (%) |
|------------------------------------------------------|---------|----------|
| Why is it important to test those at risk for HBV?   |         |          |
| Prevent the spread of infection                      | 21 (24) | 8 (16)   |
| Initiate the treatment early                         | 14 (16) | 10 (20)  |
| To be aware of our status                            | 12 (14) | 8 (16)   |
| Prevent long term complications                      | 9 (10)  | 8 (16)   |
| Because no symptoms are present until late stage    | 2 (2)   | 11 (22)  |
| I don’t know                                         | 27 (31) | 2 (4)    |
| To vaccinate those unaffected                        | 2 (2)   | 2 (4)    |
| Why you do not think it is important to test         |         |          |
| It is important                                      | 36 (73) | 22 (81)  |
| It is not important                                  | 3 (6)   | 1 (3)    |
| I don’t know                                         | 6 (12)  | 2 (7)    |
| Because it is not very common                        | 1 (2)   |          |
| I don’t have enough information to recommend the test| 2 (4)   | 1 (3)    |
| Patient has the right to decide if he wants it       | 1 (2)   | 1 (3)    |
| Because everybody has Hepatitis B                    |         | 1 (3)    |
| Barriers of access to medical care                   |         |          |
| Insurance coverage                                   | 18 (31) | 17 (40)  |
| It is easy for me                                    | 28 (48) | 16 (38)  |
| I don’t know                                         | 3 (6)   | 2 (5)    |
| Absence of good doctors                              | 1 (2)   |          |
| Lack of available doctors                            | 2 (3)   | 1 (2)    |
| Lack of time                                         | 2 (3)   |          |
| Language barrier                                     | 1 (2)   | 1 (2)    |
| Others reasons                                       | 2 (3)   | 3 (7)    |
| 2 factors above                                      | 1 (2)   | 2 (5)    |
| Uncomfortable asking for Hepatitis B testing         |         |          |
| I don’t find it uncomfortable                        | 45 (90) | 26 (76)  |
| I am afraid of the result/consequences of the infection| 2 (4)  | 2 (6)    |
| Shyness/fear of what he might think                  | 2 (4)   | 2 (6)    |
| Because it is sexually transmitted                   | 1 (2)   |          |
| Because I feel well                                  |         | 1 (3)    |
| Because it is taboo                                  |         | 3 (9)    |
| Why it will be difficult to get tested for HBV       |         |          |
| It would not be difficult for me                      | 38 (64) | 24 (61)  |
| Insurance coverage                                   | 6 (10)  | 5 (13)   |
| Fear of the results                                  | 4 (7)   | 5 (13)   |
| I don’t know                                         | 5 (8)   | 1 (2.5)  |
| Cost of the test                                     | 4 (7)   | 1 (2.5)  |
| Concerns about confidentiality                       | 2 (3)   | 1 (2.5)  |
| Lack of time                                         |         | 1 (2.5)  |
| 2 or 3 factors above                                 | 2 (3)   | 1 (2.5)  |
| Why it could be difficult to get treated for HBV     |         |          |
| It would not be difficult for me                      | 37 (65) | 19 (59)  |
| Insurance coverage                                   | 7 (12)  | 2 (7)    |
| Cost of treatment                                    | 4 (7)   | 3 (9)    |
| Treatment side effects                               | 2 (3.5) |          |
| I don’t know                                         | 3 (5)   |          |
| Lifelong treatment                                   |         | 2 (7)    |
| Lack of treatment providers                          | 1 (2)   |          |
| Other reasons                                        | 1 (2)   |          |
| 2 or 3 factors above                                 | 2 (3.5) | 6 (19)   |

Pre and Post indicate answers provided prior to and following teaching session, respectively; HBV: hepatitis B virus.
Centers may be more poorly attended, though this requires confirmation as our health center event targeted a Cambodian population, whereas our other events targeted populations of African origin. Therefore, multiple factors may influence attendance. Baseline knowledge of HBV relation to liver disease and hepatocellular carcinoma among Greater Boston immigrants ranged among countries of origin. Although HBV status of participants is unknown, most participants came from countries of high HBV endemicity, thus improved HBV knowledge is desirable. Our simple teaching intervention revealed a significant improvement in HBV knowledge, specifically including the information that (1) country of origin can be a factor of HBV risk; (2) HBV causes cancer; and (3) HBV infection may cause pathology long before any symptoms. As noted, a limitation of our teaching sessions was the ability to communicate efficacy of vaccines and treatments. We only observed a modest increase in participants aware that HBV treatment exists (50% to 66%). This may be related to our limitations to communicate that antiviral treatment to prevent or delay complications exists but no cure for HBV highlighting the need for additional outreach on this topic. While outreach into the community does cost money and time, the benefit of added HBV knowledge may outweigh these costs. Additional studies determining the percent of participants that present for HBV testing and, if positive, receive appropriate care would be required to confirm this. This study highlights the finding that (1) persons at-risk for HBV are living in the Greater Boston area; (2) there are important gaps in HBV baseline knowledge in the community; (3) teaching sessions in the community are greeted with warm reception and high participation numbers, particularly among Somalis; and (4) significant improvement in HBV understanding can be made with teaching sessions.

### COMMENTS

**Background**

Hepatitis B virus (HBV) infection and HBV related liver disease are a major public health problem worldwide. In 2016 the World Health Organization announced the initiative "Combating hepatitis B and C to reach elimination by 2030". However, many people at risk for HBV infection and HBV related liver complications are unaware that they are infected or unaware of HBV-related risks.

**Research frontiers**

They propose that reaching the final frontier of HBV elimination requires vigorous efforts to step up HBV awareness, at the global level. Awareness serves as the first step empowering at-risk persons to seek appropriate testing and care. Awareness in a given individual may also catalyze dissemination of information throughout at-risk communities. This pilot study represents a local first step in an effort to trigger rapid and accurate dissemination of HBV knowledge among persons at risk.

**Innovations and breakthroughs**

This study is innovative in that we worked to disseminate HBV directly to at-risk persons working through social networks who were brought together by community liaisons. While similar work has been initiated in the greater New York City metropolitan area, by co-author Ponni Perumalswami MD, we are not aware of similar initiatives elsewhere in the United States. This study was unique in the engagement of multiple immigrant populations (Somali, Turkish, Moroccan, etc.) simultaneously, rather than focus on any one particular group.

**Significance of the applications**

Practical applications of this study are the following: (1) the authors have demonstrated that a small group of health care workers can effectively increase HBV knowledge among relatively large groups of at-risk persons in community-based, brief teaching sessions; and (2) they have further demonstrated that there is a significant need for these teaching sessions, as many participants from extremely high risk regions for HBV are unaware of their HBV risk. They hope that this model for HBV outreach will be directly applied by others around the globe to quickly and effectively prompt at-risk persons to seek HBV care. To underscore that intention, we have provided a "toolkit" with copies of our pre/post-session questionnaire (Figure S1) and navigator card (Figure S2) for immediate use by others toward the concerted effort of 2030 HBV Eradication.

**Peer-review**

The manuscript described a teaching session to improve understanding of hepatitis B virus infection by people in a local community. The questionnaire is well designed and the procedure properly conducted.

---

**Table 4** True or false questions prior to (Pre) and following (Post) the teaching session a (%)

| Variable                                      | Pre Correct | Post correct | P value1 |
|-----------------------------------------------|-------------|--------------|----------|
| Mean of total correct answers (Std.dev) (mean ± SD) | 5.5 ± 3.3  | 7.6 ± 2.9    | < 0.001  |
| 1 Hepatitis B is an infection that affects the kidneys | 43(43)      | 35(63)       | 0.02     |
| 2 Hepatitis A turns into Hepatitis B, which then turns into Hepatitis C | 60(59)      | 49(88)       | < 0.0001 |
| 3 Hepatitis B is the most common liver infection in the world | 58(57)      | 50(89)       | < 0.0001 |
| 4 You can get hepatitis B from touching, sharing food utensils, or drinking too much alcohol | 56(55)      | 47(84)       | < 0.0001 |
| 5 The only way to get hepatitis B is through sexual contact | 44 (45)     | 34 (61)      | 0.04     |
| 6 The test for hepatitis B involves taking a small sample of blood | 67 (66)     | 47 (84)      | 0.02     |
| 7 If you have Hep B but no symptoms, no need to worry about your liver | 54 (53)     | 43 (77)      | 0.006    |
| 8 Hepatitis B infection can cause scarring of the liver and liver cancer | 59 (58)     | 44 (79)      | 0.01     |
| 9 There is no treatment for hepatitis B | 50 (50)     | 37 (66)      | 0.06     |
| 10 If you do not have hepatitis B, there is a vaccine that can prevent it | 65 (64)     | 42 (75)      | 0.20     |

1Indicates P value calculated using Fisher’s exact test. Non-significant P values are indicated in bold.
REFERENCES

1. Hepatitis B. World Health Organization 2017. Available from: URL: http://www.who.int/mediacentre/factsheets/fs234/en/

2. Bile K, Aden C, Norder H, Magnius L, Lindberg G, Nilsson L. Important role of hepatitis C virus infection as a cause of chronic liver disease in Somalia. Scand J Infect Dis 1993; 25: 559-564 [PMID: 7506842 DOI: 10.3109/00365549309008543]

3. Blanas DA, Nichols K, Bekele M, Shankar H, Bekele S, Jandorf L, Izzeldin N, Ndiaye D, Bassam M, Perumalswami PV. Adapting the Andersen model to a francophone West African immigrant population: hepatitis B screening and linkage to care in New York City. J Community Health 2015; 40: 175-184 [PMID: 25009197 DOI: 10.1007/s10900-014-9916-9]

4. Clayton-Matthews A, Watanabe P. Massachusetts Immigrants by the Numbers, Second Edition: Demographic Characteristics and Economic Footprint. In: The Immigrant Learning Center (Ed.). Malden MA, 2012

5. Cochrane A, Collins P, Horwood JP. Barriers and opportunities for hepatitis B testing and contact tracing in a UK Somali population: a qualitative study. Eur J Public Health 2016; 26: 389-395 [PMID: 26896472 DOI: 10.1093/eurpub/ckv236]

6. US Department of Human and Health Services (2014-2015). Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care and Treatment of Viral Hepatitis. Available from: URL: https://www.hhs.gov/ash/initiatives/hepatitis/

7. Fitzgerald S, Chao J, Feferman Y, Perumalswami P, Sarpel U. Hepatitis B and Hepatocellular Carcinoma Screening Practices in Chinese and African Immigrant-Rich Neighborhoods in New York City. J Racial Ethn Health Disparities 2016; 4: 626-632 [PMID: 24084784 DOI: 10.1007/s10900-013-9914-5]

8. Hu DJ, Xing J, Tohme RA, Liao Y, Pollack H, Ward JW, Holmberg SD. Hepatitis B testing and access to care among racial and ethnic minorities in selected communities across the United States, 2009-2010. Hepatology 2013; 58: 856-862 [PMID: 23359276 DOI: 10.1002/hep.26286]

9. McCabe K, African immigrants in the United States. 2011

10. Mitchell T, Armstrong GL, Hu DJ, Wasley A, Painter JA. The increasing burden of imported chronic hepatitis B—United States, 1974-2008. PLoS One 2011; 6: e27717 [PMID: 22163270 DOI: 10.1371/journal.pone.0027717]

11. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117-171 [PMID: 25530442 DOI: 10.1016/S0140-6736(14)61662-2]

12. Mukhtar NA, Kathapalia P, Hilton JF, Lau G, Yu A, Grumbach K, Nguyen TT, Chan D, Khalili M. Provider, Patient, and Practice Factors Shape Hepatitis B Prevention and Management by Primary Care Providers. J Clin Gastroenterol 2017; 51: 626-631 [PMID: 27811627 DOI: 10.1097/MCG.0000000000000738]

13. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212-2219 [PMID: 22273562 DOI: 10.1016/j.vaccine.2011.12.116]

14. Perumalswami PV, Factor SH, Kapeluszynik L, Friedman SL, Pan CQ, Chang C, Di Clemente F, Dieterich DT. Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. J Hepatol 2013; 58: 890-897 [PMID: 23333446 DOI: 10.1016/j.jhep.2013.01.004]

15. Shah SA, Chen K, Marneni S, Benchekroune G, Ariganjoye R, Purswani M, Adeniyi AO, Bainbridge R, Timoney MT, Hagmann S. Hepatitis B awareness and knowledge in hepatitis B surface antigen-positive parturient immigrant women from West Africa in the Bronx, New York. J Immigr Minor Health 2015; 17: 302-305 [PMID: 24048743 DOI: 10.1007/s10903-013-9914-5]

16. Shankar H, Blanas D, Bichoupan K, Ndiaye D, Carmdody E, Martel-Laferrerire V, Culpepper-Morgan J, Dieterich DT, Branch AD, Bekele M, Nichols K, Perumalswami P, A Novel Collaborative Community-Based Hepatitis B Screening and Linkage to Care Program for African Immigrants. Clin Infect Dis 2016; 62 Suppl 4: S289-S297 [PMID: 27190318 DOI: 10.1093/cid/ciw090]

17. Shire AM, Sandhu DS, Kaiya JK, Oseini AM, Yang JD, Chaiteerakij R, Mettler TA, Giama NH, Roberts RO, Therneau TM, Petersen GM, Knutson KL, Roberts LR. Viral hepatitis among Somali immigrants in Minnesota: association of hepatitis C with hepatocellular carcinoma. Mayo Clin Proc 2012; 87: 17-24 [PMID: 22212964 DOI: 10.1016/j.mayocp.2011.08.001]

18. Sriphanlop P, Jandorf L, Kairouz C, Thelemaque L, Shankar H, Perumalswami P. Factors related to hepatitis B screening among Africans in New York City. Am J Health Behav 2014; 38: 745-754 [PMID: 24933144 DOI: 10.5933/AJHB.38.5.12]

P- Reviewer: Dourakis SP, Guan YS, Sporea I, Wang L
S- Editor: Qi Y
L- Editor: A
E- Editor: Ma YJ
